as 07-26-2024 4:00pm EST
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | BERKELEY |
Market Cap: | 204.1M | IPO Year: | 2021 |
Target Price: | $15.67 | AVG Volume (30 days): | 2.4M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.46 | EPS Growth: | N/A |
52 Week Low/High: | $1.50 - $8.33 | Next Earning Date: | 08-06-2024 |
Revenue: | $33,404,000 | Revenue Growth: | 127.41% |
Revenue Growth (this year): | -65.26% | Revenue Growth (next year): | 7.53% |
CRBU Breaking Stock News: Dive into CRBU Ticker-Specific Updates for Smart Investing
BioPharma Dive
10 days ago
Simply Wall St.
10 days ago
GlobeNewswire
18 days ago
MT Newswires
18 days ago
CNW Group
2 months ago
PR Newswire
2 months ago
Business Wire
2 months ago
AFP
2 months ago
The information presented on this page, "CRBU Caribou Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.